Infliximab trough level measured during treatment induction may be predictive of the loss of response to Infliximab during treatment maintenance in inflammatory bowel disease patients: a longitudinal observational retrospective study

被引：0
|
作者：
Liefferinckx, C. [1 ]
Minsart, C. [2 ]
Cremer, A. [1 ]
Amininejad, L. [1 ]
Toubeau, J. -F. [3 ]
Quertinmont, E. [2 ]
Deviere, J. [1 ]
Van Gossum, A. [1 ]
Franchimont, D. [1 ]
机构：
[1] Free Univ Brussels, Erasme Hosp, Gastroenterol, B-1050 Brussels, Belgium
[2] Univ Libre Bruxelles, Lab Expt Gastroenterol, Brussels, Belgium
[3] Univ Mons, Dept Elect Engn, B-7000 Mons, Belgium
来源：
JOURNAL OF CROHNS & COLITIS | 2016年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P405
引用
收藏
页码：S303 / S304
页数：2
相关论文
共 50 条
  • [21] Prediction of treatment failure during infliximab induction therapy in inflammatory bowel disease patients based on pharmacokinetic and pharmacodynamic modeling
    Kimura, Koji
    Yoshida, Atsushi
    Katagiri, Fumihiko
    Takayanagi, Risa
    Yamada, Yasuhiko
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 150
  • [22] Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study
    Roblin, Xavier
    Boschetti, Gilles
    Duru, Gerard
    Williet, Nicolas
    Deltedesco, Emilie
    Phelip, Jean M.
    Peyrin-Biroulet, Laurent
    Nancey, Stephane
    Flourie, Bernard
    Paul, Stephane
    INFLAMMATORY BOWEL DISEASES, 2017, 23 (11) : 2048 - 2053
  • [23] Smoking is associated with low trough serum infliximab levels and presence of anti-infliximab antibody in maintenance treatment of inflammatory bowel disease (IBD)
    Kong, J. Y.
    Bundell, C. S.
    Pawlik, J.
    Hollingsworth, P. N.
    Forbes, G. M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 59 - 59
  • [24] Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease
    Luber, Raphael P.
    Dawson, Luke
    Munari, Stephanie
    Kariyawasam, Viraj C.
    Martin, Catherine
    Gibson, Peter R.
    Sparrow, Miles P.
    Ward, Mark G.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (04) : 990 - 998
  • [25] RETROSPECTIVE STUDY OF DOSE ESCALATION WITH ADALIMUMAB, INFLIXIMAB, AND VEDOLIZUMAB IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
    Zhang, K. H.
    Singh, H.
    Twardowski, R.
    Lu, C.
    Wan, Y.
    Null, K.
    VALUE IN HEALTH, 2020, 23 : S143 - S143
  • [26] Infliximab trough levels are associated with transmural healing during maintenance treatment in pediatric Crohn's disease patients
    Kang, Ben
    Choi, So Yoon
    Choi, Young Ok
    Kim, Mi Jin
    Jeon, Tae Yeon
    Choe, Yon Ho
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 64 - 65
  • [27] Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment
    Laas, K
    Peltomaa, R
    Kautiainen, H
    Puolakka, K
    Leirisalo-Repo, M
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (07) : 924 - 928
  • [28] Low Doses of Azathioprine are Effective in Combination With Infliximab in Inflammatory Bowel Disease but May not be During Induction Therapy
    Roblin, Xavier
    Flourie, B.
    Paul, Stephane
    JOURNAL OF CROHNS & COLITIS, 2018, 12 (05): : 628 - 628
  • [29] Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy
    van Hoeve, Karen
    Tabib, Nasim Sadat Seyed
    Dreesen, Erwin
    Tops, Sophie
    Hoffman, Ilse
    Gils, Ann
    Ferrante, Marc
    Vermeire, Severine
    JOURNAL OF PEDIATRICS, 2022, 240 : 150 - +
  • [30] THERAPEUTIC DRUG MONITORING OF INFLIXIMAB FOR THE MANAGEMENT OF LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE: AN OBSERVATIONAL MULTICENTER STUDY
    Guidi, L.
    Pugliese, D.
    Tonucci, T. Panici
    Tolusso, B.
    Cantoro, L.
    Kohn, A.
    Balestrieri, P.
    Cicala, M.
    Civitelli, F.
    Viola, F.
    Bertani, L.
    Costa, F.
    Rapaccini, G. L.
    Armuzzi, A.
    DIGESTIVE AND LIVER DISEASE, 2017, 49 : E93 - E93
12345